Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

8.3%

1 terminated/withdrawn out of 12 trials

Success Rate

75.0%

-11.6% vs industry average

Late-Stage Pipeline

67%

8 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

5 recruiting3 with results

Enrollment Performance

Analytics

Phase 3

6(50.0%)

Phase 1

3(25.0%)

Phase 4

2(16.7%)

Phase 2

1(8.3%)

12Total

Phase 3(6)

Phase 1(3)

Phase 4(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT03049189Phase 3Active Not Recruiting

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Role: collaborator

NCT07742735Phase 3Recruiting

A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)

Role: collaborator

NCT06940830Phase 4Recruiting

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

Role: collaborator

NCT06716814Phase 3Recruiting

Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

Role: collaborator

NCT06579144Phase 1Completed

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

Role: collaborator

NCT05413850Phase 1Recruiting

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Role: collaborator

NCT06752850Phase 4Active Not Recruiting

A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

Role: collaborator

NCT03165734Phase 3Active Not Recruiting

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Role: collaborator

NCT06782373Phase 2Recruiting

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

Role: collaborator

NCT04907968Phase 1Terminated

Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer

Role: collaborator

NCT02557035Phase 3Completed

An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting

Role: collaborator

NCT02517021Phase 3Completed

A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

Role: collaborator

All 12 trials loaded